Ranking Invest

Ultragenyx Pharmaceutical Inc.

Segmento: Healthcare Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Indicadores Básicos

Valor de Mercado

$ 2.80 Bi

IVR

-0.72

IVR2

-0.77

Índices de Previsibilidade

Faturamento

0.08

Lucro

0.16

Margem

0.22

Índices de Tendência

Faturamento

10.73

Lucro

-1.54

Margem

5.24

Índices de Endividamento

DIV/PAT

-0.65

DIV/L4T

0.16

Dívida Líquida

-$ 88.78 Mi

Patrimônio Líquido

$ 137.25 Mi

L4T

-$ 549.58 Mi

MM4T

-93.65%

Dívidas
Dividendos
Cotação: $29.12

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre